G771C polymorphism in the MLXIPL gene is associated with a risk of coronary artery disease in the Chinese: A case-control study

Cardiology

Volumn 114, Issue 3, 2009, Pages 174-178

  Pan, Ling Ai ^a   Chen, Yu Cheng ^a   Huang, Hao ^a   Zhang, Li ^a   Liu, Rui ^b   Li, Xian ^b   Qiang, Ou ^b   Zeng, Zhi ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Coronary artery disease; MLXIPL gene; Polymorphism

Indexed keywords

TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHINESE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CASE-CONTROL STUDIES; CHINA; CORONARY ARTERY DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 67649435687     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000226610     Document Type: Article

References (31)

1. World Health Organization: World Health Statistics Annual, 1993. Geneva, World Health Organization, 1994.
2. Glass CK, Witztum JL: Atherosclerosis: the road ahead. Cell 2001;104:503-516.
3. Namboodiri KK, et al: The Collaborative Lipid Research Clinics Family Study: biological and cultural determinants of familial resemblance for plasma lipids and lipoproteins. Genet Epidemiol 1985;2:227-254.
4. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J III: Factors of risk in the development of coronary heart disease - six year follow-up experience. The Framingham Study. Ann Intern Med 1961;55:33-50.
5. Miller GJ, Miller NE: Plasma high-density-lipoprotein concentration and development of ischaemic heart disease. Lancet 1975;i:16-19.
6. Grundy SM: Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006;47:1093-1100.
7. Grundy SM: Does a diagnosis of metabolic syndrome have value in clinical practice? Am J Clin Nutr 2006;83:1248-1251.
8. Grundy SM: Drug therapy of the metabolic syndrome: minimizing the emerging crisis of polypharmacy. Nat Rev Drug Discov 2006;5:295-309.
9. Moller DE, Kaufman KD: Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 2005;56:45-62. (Pubitemid 40299773)
10. Sattar N: The metabolic syndrome: should current criteria influence clinical practice? Curr Opin Lipidol 2006;17:404-411.
11. Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 2005;365:1415-1428.
12. Reaven GM: The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr 2006;83:1237-1247.
13. Ferrannini E: Is insulin resistance the cause of the metabolic syndrome? Ann Med 2006;38:43-51.
14. Gale EA: The myth of the metabolic syndrome. Diabetologia 2005;48:1679-1683.
15. Kahn R, Buse J, Ferrannini E, Stern M: The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289-2304. (Pubitemid 41242486)
16. Reaven GM: The metabolic syndrome: requiescat in pace. Clin Chem 2005;51:931-938.
17. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-553.
18. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001;285:2486-2497.
19. Alberti KG, Zimmet P, Shaw J: The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-1062. (Pubitemid 41338752)
20. Galassi A, Reynolds K, He J: Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006;119:812-819. (Pubitemid 44415613)
21. Jaspal S, John C, Carlos A: Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. Nat Genet 2008;40:149-151.
22. Kathiresan S, et al: Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 2008;40:189-197. (Pubitemid 351171402)
23. Chanock SJ, Manolio T, Collins FS: Replicating genotype-phenotype associations. Nature 2007;447:655-660.
24. O'Donnell CJ, Lindpaintner K: Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. Circulation 1998;97:1766-1772.
25. Steinberg D, Gotto AM: Preventing coronary artery disease by lowering cholesterol levels;fifty years from bench to bedside. JAMA 1999;282:2043-2050.
26. Hokason JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-219.
27. Ordovas JM: HDL genetics, candidate genes, genome wide scans and gene-environment interactions. Cardiovasc Drugs Ther 2002;16:273-281.
28. Uveda K, Repa JJ: Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab 2006;4:107-110.
29. Ma L, Robinson LN, Towle HC: ChREBP/ Mlx is the principal mediator of glucose-induced gene expression in the liver. J Biol Chem 2006;281:28721-28730. (Pubitemid 44507014)
30. Li MV, Chang B, Imamura M, Poungvarin N, Chan L: Glucose-dependent transcriptional regulation by an evolutionarily conserved glucose-sensing module. Diabetes 2006;55:1179-1189. (Pubitemid 44195353)
31. Diamond J: The double puzzle of diabetes. Nature 2003;423:599-602.